GENFIT: Results of May 22, 2024 Shareholders Meeting

Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), May 22, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company specializing in treatments for rare and severe liver diseases, revealed the outcomes of its Combined Shareholders Meeting held on May 22, 2024. The first convening of the meeting achieved a quorum of 27.25%, leading to the approval of all proposed resolutions.

Detailed voting outcomes for each resolution will soon be accessible on the Investors & Media section of GENFIT’s website.

About GENFIT

GENFIT is a biopharmaceutical company in advanced stages of development, dedicated to addressing the unmet medical needs of patients suffering from rare and critical liver diseases. The company has been a leader in liver disease research and development for over 20 years, which has allowed it to establish a diverse and rapidly progressing R&D portfolio.

The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF). GENFIT's ACLF program includes five key assets: VS-01, NTZ, SRT-015, CLM-022, and VS-02-HE. These assets operate through different mechanisms, utilizing various administration routes. Additionally, GENFIT is exploring treatments for other severe conditions such as cholangiocarcinoma (CCA), urea cycle disorder (UCD), and organic acidemia (OA).

GENFIT’s proficiency in developing potent molecules from early stages to pre-commercialization has been proven with the success of its 52-week Phase 3 ELATIVE® study, which evaluated elafibranor in treating Primary Biliary Cholangitis (PBC). Beyond therapeutic solutions, GENFIT is also invested in diagnostics, including NIS4® for Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) and TS-01, which monitors blood ammonia levels.

Headquartered in Lille, France, GENFIT has offices in Paris, Zurich, and Cambridge, MA. The company is publicly traded on the Nasdaq Global Select Market and Euronext Paris. In 2021, Ipsen, a major pharmaceutical company, acquired an 8% stake in GENFIT, becoming one of its largest shareholders.

Conclusion

GENFIT’s recent Shareholders Meeting marked a significant milestone with the approval of all proposed resolutions. As the company continues to advance its portfolio of innovative treatments and diagnostics for severe liver diseases, it remains committed to addressing the significant unmet medical needs of patients worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!